Analysts expect that pSivida Corp. (NASDAQ:PSDV) will announce ($0.13) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for pSivida’s earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.14). pSivida reported earnings of ($0.15) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 13.3%. The firm is expected to announce its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that pSivida will report full-year earnings of ($0.54) per share for the current year, with EPS estimates ranging from ($0.56) to ($0.52). For the next financial year, analysts anticipate that the business will report earnings of ($0.47) per share, with EPS estimates ranging from ($0.52) to ($0.41). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for pSivida.
pSivida (NASDAQ:PSDV) last released its quarterly earnings results on Wednesday, February 7th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. pSivida had a negative return on equity of 205.82% and a negative net margin of 882.37%. The firm had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.48 million.
PSDV has been the topic of several recent analyst reports. Laidlaw initiated coverage on pSivida in a report on Wednesday, November 8th. They issued a “buy” rating and a $5.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of pSivida in a report on Wednesday, November 8th. ValuEngine lowered pSivida from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. B. Riley set a $5.00 price objective on pSivida and gave the company a “buy” rating in a research report on Monday, December 4th. Finally, Northland Securities reiterated a “buy” rating and set a $10.00 price objective on shares of pSivida in a research report on Monday, December 11th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $7.57.
Shares of pSivida (NASDAQ:PSDV) opened at $1.10 on Thursday. pSivida has a 1-year low of $0.93 and a 1-year high of $2.45.
Several institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC increased its position in shares of pSivida by 4.1% during the 4th quarter. Renaissance Technologies LLC now owns 1,524,000 shares of the company’s stock valued at $1,646,000 after purchasing an additional 59,900 shares during the last quarter. Geode Capital Management LLC increased its position in shares of pSivida by 75.0% during the 4th quarter. Geode Capital Management LLC now owns 240,631 shares of the company’s stock valued at $259,000 after purchasing an additional 103,150 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in shares of pSivida during the 4th quarter valued at about $173,000. Finally, OxFORD Asset Management LLP bought a new position in shares of pSivida during the 2nd quarter valued at about $118,000. Hedge funds and other institutional investors own 10.06% of the company’s stock.
pSivida Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.